Evolution of the Average Target: Forvia (ex-Faurecia)

Evolution of the Target Price: Forvia (ex-Faurecia)

Changes in Analyst Recommendations: Forvia (ex-Faurecia)

6a1.YhOOEuPmZ5XdN4ZY7NHsccjDjAKxw_SsdDTIKhGEO14.Ulv-ILCUHd6qD9wZq7KdAqugz0yEmcT9PEz-U3fJUSsIUshY0I9Kyr519Q~283989c213596656472ef9a92fd162a7
03-11 Forvia slips despite support from Citigroup Zonebourse
03-04 Forvia: Resilient FY25 in a Tough Environment; Ambitious 2028 Targets Unveiled at CMD Alphavalue
02-26 Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna… Zonebourse
01-20 Forvia lifts EPS after Q4 pre-close Alphavalue
11-25 Forvia revises EPS outlook after non-cash charge Alphavalue
21/10/25 Forvia: UBS Maintains Neutral Rating After Q3 Revenue in Line with Expectations Zonebourse
21/10/25 Forvia: UBS still neutral after quarterly results Zonebourse
20/10/25 Forvia: Q3 results impacted by geographic mix and FX headwinds; FY25 guidance confirmed Alphavalue
12/09/25 The stock market regains its cloak of invincibility Zonebourse
07/08/25 Forvia: Opinion change, from Sell to Reduce Alphavalue
30/07/25 Analysts' opinions of the day: Kering splits, news on Abivax, Soitec and Novo Nordisk Zonebourse
29/07/25 Forvia: Deutsche Bank downgrades stock Zonebourse
29/07/25 Forvia: Solid H1 results ahead of expectations, FY25 guidance confirmed Alphavalue
29/07/25 Forvia: Oddo BHF raises target price Zonebourse
24/07/25 Forvia: NAV cut by -14.8% Alphavalue
03/07/25 Forvia: Target upgrade by 14.5% Alphavalue
27/06/25 Forvia: Berenberg still a buyer, seeing positive surprises Zonebourse
22/04/25 FORVIA : Receives a Buy rating from Deutsche Bank ZD
22/04/25 Forvia: Oddo BHF lowers target price Zonebourse
17/04/25 Forvia: Stronger than expected Q1 and FY25 guidance maintained despite tariff risks Alphavalue
01/04/25 Forvia: Opinion change, from Buy to Reduce Alphavalue
26/03/25 TP Icap Midcap Kicks Off Forvia Coverage with Hold Rating MT
26/03/25 Forvia: TP ICAP Midcap initiates coverage on hold Zonebourse
19/03/25 FORVIA : UBS reaffirms its Neutral rating ZD
06/03/25 Forvia: Soft FY24 results amid a tough environment, weaker than expected FY25 guidance Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+63.6%
+8.12%
+16.7%
+14.08%
+30.91%
+32.48%
+18.98%
+16.54%
+43.35%
+18.92%
Average +26.37%
Weighted average by Cap. +20.00%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
9.820EUR
Average target price
16.07EUR
Spread / Average Target
+63.60%
High Price Target
39.00EUR
Spread / Highest target
+297.15%
Low Price Target
12.00EUR
Spread / Lowest Target
+22.20%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue Adrien Brasey
TP ICAP Midcap
UBS David Lesne
Stifel Nicolaus
Berenberg Bank
GOLDMAN SACHS Philipp Konig
JEFFERIES Himanshu Agarwal
DEUTSCHE BANK RESEARCH Christoph Laskawi
JPMORGAN Jose Asumendi
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
9.820EUR
Average target price
16.07EUR
Spread / Average Target
+63.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. FRVIA Stock
  4. Consensus Forvia (ex-Faurecia)
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW